Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

Table 3 Baseline factors associated with infliximab dose escalation (n = 5174 initiators)

Factor	Adjusted* odds ratio (95% CI)
Physician ownership of infusion practice	1.25 (1.09–1.44)
Patient age (5 year increments)	0.93 (0.89–0.96)
Male sex	1.20 (1.04–1.40)
Chronic pulmonary disease	0.84 (0.74–0.95)
Disability	0.84 (0.72–0.98)
Dual eligibility	0.79 (0.66–0.94)

*Also adjusted for race, use of other conventional synthetic DMARDs, use of oral glucocorticoid, NSAIDs, opioids, statins, anti-hypertensive medications, lipid lowering medications, anti-depressants, and breast cancer screening, none of which were significant

ISSN: 1478-6362